We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byPrecious Ellenwood
Modified over 2 years ago
Montalescot G, et al. Lancet 2009;373:723-31
Trial profile Montalescot G, et al. Lancet 2009;373:723-31
Baseline characteristics of STEMI cohort, by drug allocation and type of PCI Montalescot G, et al. Lancet 2009;373:723-31
Major efficacy and safety endpoints at 30 days Montalescot G, et al. Lancet 2009;373:723-31
Major efficacy and safety endpoints at 15 months Montalescot G, et al. Lancet 2009;373:723-31
Kaplan-Meier curves for selected endpoints Montalescot G, et al. Lancet 2009;373:723-31
Trial profile Fox K et al. Lancet 2008;372:
TRITON TIMI-38 STEMI cohort Clopidogrel Under Fire: Is Prasugrel in Primary PCI or Recent MI Superior? Insights From TRITON-TIMI-38 Gilles Montalescot,
Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: An International Randomised Evaluation One year follow-up.
TRITON TIMI-38 STEMI cohort Primary End Point (CV death, MI and stroke at 15 months) Adapted from Montalescot et al. ESC Time (days)
Trial profile Mann JF et al. Lancet 2008;372:
Sibbing D, et al. J Am Coll Cardiol 2009;53:
Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
A Randomized, Double-blind, Placebo-controlled Trial of Intravenous Erythropoietin in Patients with ST-Segment Elevation Myocardial Infarction – Primary.
ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.
Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.
Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Frequency of Clostridium difficile infection (CDI) transmission via ward contact with a known case Retrospective, observational study (22 months; 1 laboratory.
Enoxaparin in primary PCI From FINESSE to ATOLL G. Montalescot Institut de Cardiologie Pitié-Salpêtrière Hospital Paris, France The FINESSE Trial is supported.
Resolute all comers trial Objective:To compare the efficacy and safety of the new generation ZES stent versus the everolimus eluting stent. Study:Multicenter,
© 2017 SlidePlayer.com Inc. All rights reserved.